(Mary Dowling – Independent Sentinel) The U.S. Food and Drug Administration added a warning to gonadotropin-releasing hormone (GnRH) agonists, commonly known as “puberty blockers.” They indicated that there were serious risks for youth who take them.
The U.S. Food and Drug Administration (FDA) identified six cases in females between the ages of 5 and 12, who were taking GnRH agonists, which presented “a plausible association between GnRH agonist use and pseudotumor cerebri.” Continue reading